Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)
2018-001749-15Phase 3Unknown
- Sponsor
- Aimmune Therapeutics , Inc.
- Start
- Feb 2019
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peanut allergy comparing AR101 oral immunotherapy with Placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Safety and tolerability. Status: unknown.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2018-001749-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001749-15.